Compounded Testosterone Cream for Women: Doses, Benefits, and What the Evidence Actually Shows

Why Women Need Testosterone at All

Testosterone is not a male-only hormone. Women produce it in the ovaries and adrenal glands, and serum concentrations peak in the mid-20s before declining roughly 50% by natural menopause. That drop matters clinically. Testosterone acts on androgen receptors throughout the brain, clitoris, vaginal wall, bone, and skeletal muscle, contributing to desire, arousal, energy, and lean mass.

The 2019 Global Consensus Position Statement on Testosterone Therapy for Women, endorsed by ten international medical societies, states: "There is a sufficiency of evidence to support the use of testosterone therapy for postmenopausal women with HSDD." [1] That language is deliberate. The societies did not call the evidence "promising" or "emerging." They called it sufficient.

What the evidence does not yet support is routine testosterone use for premenopausal women, women without a diagnosable sexual complaint, or supraphysiologic dosing aimed at athletic performance. Staying within those boundaries is what separates evidence-based prescribing from off-label experimentation.

What HSDD Is and How Common It Is

Hypoactive sexual desire disorder is defined as persistently low or absent sexual desire that causes personal distress. Prevalence estimates vary by diagnostic criteria, but the PRESIDE study (N = 31 to 581 U.S. women) found that 38.7% of women aged 45, 64 reported low sexual desire and 12.3% reported distress attributable to it, meeting the threshold for HSDD. [2] After surgical menopause, bilateral oophorectomy drops testosterone by approximately 50% within 24 hours, making iatrogenic HSDD one of the most predictable surgical sequelae in gynecology.

HSDD is not a mood disorder and it does not respond reliably to antidepressants. Distinguishing it from depression-related anhedonia or relationship-based desire discrepancy is a clinical requirement before any hormonal or pharmacological treatment is started.

The Clinical Trial Evidence for Testosterone in Women

Three landmark trials anchor the prescribing rationale.

The INTIMATE SM1 trial randomized 562 surgically menopausal women to testosterone patch (300 mcg/day) or placebo for 24 weeks. The testosterone group reported a mean increase of 2.1 satisfying sexual events per 4-week period versus 0.7 in the placebo group (P<0.001). [3] Scores on the Female Sexual Function Index (FSFI) desire subscale improved by 1.2 points versus 0.4 for placebo.

The APHRODITE trial (N = 814 naturally postmenopausal women) tested the same 300 mcg/day patch against placebo for 52 weeks. Women receiving testosterone had 4.9 satisfying sexual events per 4-week period versus 4.0 on placebo at week 52, a statistically significant difference (P<0.05). [4]

A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology pooled 36 randomized controlled trials (N = 8,480 women). Testosterone therapy produced statistically significant improvements in desire (standardized mean difference 0.42), arousal (SMD 0.38), and orgasm (SMD 0.30) compared with placebo or comparator across formulations, including cream, gel, and patch. [5]

No serious cardiovascular, hepatic, or breast-cancer signals emerged in trials using physiologic dosing. The meta-analysis authors noted that trial durations were rarely longer than 6 months, so long-term safety data beyond 24 months remain limited. Oral formulations were specifically excluded from the consensus recommendation because of adverse lipid effects from first-pass hepatic metabolism.

How Compounded Testosterone Cream Works and What Dose Is Used

Transdermal cream bypasses first-pass liver metabolism, delivering testosterone directly into systemic circulation through the skin. Compounding pharmacies typically prepare concentrations between 0.5 mg/0.5 mL and 2 mg/0.5 mL, calibrated to mimic the upper end of normal female serum testosterone (15 to 70 ng/dL total testosterone by LC-MS/MS assay).

Common application sites include the inner labia minora, inner thigh, or inner arm. Genital application produces approximately 4-fold higher local tissue concentrations than arm application for the same dose, which can be clinically relevant when genitourinary symptoms accompany low desire. [6] Application should rotate to avoid skin atrophy or fibrosis at a single site.

The prescribing target is a serum free testosterone level in the upper quartile of the normal premenopausal range, not above it. Most protocols call for:

• Weeks 1, 4: 0.5 to 1 mg/day
• Weeks 5, 12: Recheck free testosterone and SHBG; titrate to response
• Maintenance: 1 to 2 mg/day, typically applied once daily

Onset for libido changes is 4 to 12 weeks. Body-composition and energy changes, if they occur, generally require 3 to 6 months of consistent use.

How Compounded Testosterone Compares with FDA-Approved Options

No FDA-approved testosterone product exists for women in the United States. The agency rejected the Intrinsa testosterone patch (Procter & Gamble) in 2004 due to insufficient long-term safety data, particularly regarding breast cancer and cardiovascular risk. [7] Two non-androgen medications are FDA-approved for HSDD:

Flibanserin (Addyi, 100 mg oral at bedtime) was approved in 2015 for premenopausal women with HSDD. Pooled data from three Phase 3 trials (N = 2,400) showed a mean increase of 0.5 satisfying sexual events per 4 weeks versus placebo, with response rates of 8 to 13% for "much improved" or "very much improved" on the Patient Global Impression of Change scale. [8] The drug carries a black-box warning for hypotension and syncope with alcohol, CNS depressants, and CYP3A4 inhibitors. It is not approved for postmenopausal women.

Bremelanotide (Vyleesi, 1.75 mg subcutaneous injection before sexual activity) was approved in 2019, also for premenopausal HSDD. The RECONNECT trials (N = 1,267) showed a mean increase of 0.7 satisfying sexual events per 4 weeks and statistically significant improvement in desire and distress. [9] Transient nausea occurred in 40% of participants, and 13% discontinued due to adverse events. It is administered on demand, not daily.

Neither flibanserin nor bremelanotide is approved for postmenopausal women. For that population, compounded testosterone represents the most evidence-supported pharmacologic option currently available in the U.S.

HealthRX Clinical Decision Framework: Matching the Patient to the Right Agent

| Patient Profile | First-Line Option | Rationale | |---|---|---| | Premenopausal, HSDD, no androgen deficiency signs | Flibanserin (Addyi) | FDA-approved; non-hormonal | | Premenopausal, HSDD, prefers on-demand dosing | Bremelanotide (Vyleesi) | Single-dose before activity | | Postmenopausal, HSDD, no GSM | Testosterone cream 1 to 2 mg/day | Strongest evidence for this cohort | | Postmenopausal, HSDD + GSM (dryness, dyspareunia) | Testosterone cream + vaginal estradiol or vaginal DHEA | Addresses both central desire and local tissue changes | | Surgical menopause, abrupt testosterone loss | Testosterone cream; initiate early post-op | Rapid androgen decline warrants prompt treatment |

Vaginal Estradiol: Addressing the Local Tissue Component

Vaginal testosterone cream treats desire centrally and, to a degree, locally. Genitourinary syndrome of menopause (GSM), which affects up to 50% of postmenopausal women, involves distinct pathology: vaginal mucosal thinning, reduced lubrication, elevated vaginal pH, and recurrent urinary tract infections attributable to estrogen deficiency rather than androgen deficiency. [10]

Vaginal estradiol (brand name Estrace, 0.01% cream; also available as Vagifem and Imvexxy ring/tablet) delivers estradiol locally with minimal systemic absorption. The package insert for Estrace 0.01% cream documents less than 0.01 ng/mL systemic estradiol at maintenance dosing (0.5 g twice weekly). The North American Menopause Society (NAMS) 2023 position statement affirms that low-dose vaginal estrogen does not require concomitant progestogen in women with a uterus. [11] Standard dosing is 0.5 to 1 g intravaginally once daily for 2 weeks, then twice weekly long-term.

Women using testosterone cream for HSDD who also have GSM symptoms benefit most from combining testosterone with vaginal estradiol. The two therapies act on different receptor systems and different symptom clusters.

Vaginal DHEA (Prasterone / Intrarosa): The Dual-Action Option

Prasterone (brand name Intrarosa, 6.5 mg vaginal insert once nightly) is FDA-approved for dyspareunia due to GSM. DHEA is a precursor steroid that vaginal epithelial cells convert locally into both estradiol and testosterone via intracrine metabolism, which means systemic sex steroid levels remain largely unchanged. [12]

The AMEC trial (N = 218) showed prasterone produced statistically significant improvements in vaginal dryness, dyspareunia severity, and vaginal pH at 12 weeks compared with placebo. [13] Secondary analyses demonstrated improvements in sexual desire and arousal scores, making prasterone conceptually attractive for women who have both GSM and desire symptoms but prefer a single agent.

Compounded DHEA cream (typically 3.5 to 10% topical) is also available through compounding pharmacies, though the clinical database supporting the compounded form is smaller than the Intrarosa trial data. Women who cannot afford or access Intrarosa may discuss compounded DHEA with their prescriber as a pragmatic alternative.

Safety, Monitoring, and When to Stop

Physiologic testosterone dosing in women is generally well-tolerated. Adverse effects scale with dose and duration above the normal female range:

• Acne: Occurs in 4 to 8% at physiologic doses, more commonly with supratherapeutic levels [5]
• Increased hair growth: Reported in 3 to 6% of women in trial data [5]
• Clitoral enlargement: Rare at standard doses; more common with male-range testosterone levels
• Voice deepening: Uncommon and potentially irreversible; warrants dose reduction or cessation
• Polycythemia: Monitor hematocrit; relevant at higher doses or in women with baseline elevated red cell mass

Lab monitoring protocol at HealthRX follows these intervals: baseline total testosterone, free testosterone (equilibrium dialysis method), SHBG, and hematocrit before prescribing; repeat at 6 to 8 weeks after initiation; then every 6 months at stable dose. The target is free testosterone at or below the upper limit of the normal female reference range by LC-MS/MS assay (typically free T < 8 pg/mL at most laboratory reference ranges).

Testosterone therapy is not recommended in women with hormone receptor-positive breast cancer history, active liver disease, or current pregnancy. The 2019 consensus position explicitly states that data are insufficient to support use in women with these conditions. [1]

Getting a Prescription: What the Telehealth Process Looks Like

Because no FDA-approved female testosterone product exists commercially, all prescriptions require a compounding pharmacy. A licensed prescriber writes a compounded prescription specifying concentration (e.g., testosterone 1 mg/0.5 mL in a lipoderm or PLO gel base), quantity, and refill schedule. Telehealth platforms can legally prescribe compounded testosterone across most U.S. states following a synchronous video or asynchronous clinical evaluation.

Typical out-of-pocket costs run $40, $80 per month at an accredited compounding pharmacy (PCAB-accredited facilities adhere to USP 795 standards for non-sterile compounds). Insurance rarely covers compounded hormones; some HSA/FSA plans do.

The prescriber should document the HSDD diagnosis, confirm distress criterion is met, review baseline labs, and discuss alternatives including flibanserin and bremelanotide before initiating testosterone. That documentation protects both patient and clinician in the absence of an FDA-approved indication.

What Happens if Testosterone Alone Is Not Enough

Sexual desire exists at the intersection of hormones, neurotransmitters, relationship factors, pelvic floor function, and mental health. Testosterone addresses the hormonal substrate, but women with comorbid pelvic floor dysfunction, provoked vestibulodynia, or relationship distress often need adjunctive care.

Pelvic floor physical therapy (PFPT) reduces dyspareunia in up to 72% of women with vaginismus or high-tone pelvic floor dysfunction in observational data. [14] Cognitive behavioral therapy targeting sexual self-efficacy has Level A evidence for HSDD from the NAMS guidelines. Combining hormonal treatment with PFPT or sex therapy consistently outperforms either alone in randomized data.

Women who do not respond to 12 weeks of testosterone at target serum levels should have their diagnosis re-evaluated. Non-response may indicate that desire deficit is not androgen-driven, that relationship or psychological factors predominate, or that an alternative diagnosis such as provoked vestibulodynia is the primary problem.

Practical Tips for Starting Compounded Testosterone Cream

Store the cream at room temperature, away from direct sunlight. Apply with a measured applicator or calibrated syringe to ensure dose consistency. Wash hands after application if using an extremity site, and avoid skin-to-skin contact with male partners or children for at least 2 hours post-application to prevent inadvertent transfer. The FDA has issued transfer warnings for male testosterone gels, and the same precaution applies to female formulations. [15]

Alcohol-based cream vehicles dry faster and may cause less transfer risk than oil-based vehicles. Ask the compounding pharmacist specifically about the base used.

A serum testosterone level drawn in the morning, 12 hours after evening application, gives the most reliable trough reading for dose adjustment. Random mid-day draws after morning application reflect peak rather than trough and will read artificially high.